Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma

Table 1 Clinical characteristics of the patients included in this study (n = 31)

Characteristics	n (%)
Patient
Gender (M/F)	22/9
Age, yr (range)	47.6 ± 8.8 (28-61)
Stage status
III	18 (58.06)
IV	13 (41.93)
Complications
Seroperitoneum	14 (45.16)
Hypoproteinemia	17 (54.83)
Choloplania	8 (25.80)
ECOG performance status
0	3 (9.67)
1	18 (58.06)
2	10 (32.25)
Past history before treatment
Surgery	4 (12.90)
TACE	7 (22.58)
Chemotherapy	1 (3.22)
Surgery + TACE	8 (25.80)
Surgery + chemotherapy	2 (6.45)
TACE + chemotherapy	3 (9.67)
Initial treatment	6 (19.35)

M: Male; F: Female; ECOG: Eastern Cooperative Oncology Group; TACE: Transcatheter arterial chemoembolization.

Table 2 Immunity indices before and after treatment

Group	Pre-treatment	Post-treatment	P value
CD3+	70.44% ± 6.68%	72.67% ± 6.22%	0.55
CD4+	35.78% ± 3.51%	45.83% ± 2.48%	0.016
CD3+CD8+	24.61% ± 4.19%	39.67% ± 3.38%	0.008
CD3+CD56+	5.94% ± 0.87%	10.72% ± 0.67%	0.001

Table 3 Treatment-related adverse events (n = 31)

Side effects	n (%)
Abdominal side effects
Abdominal pain	3 (9.67)
Abdominal erubescence	5 (16.12)
Abdominal lesser tubercle	1 (3.22)
Systemic side effects
Slight fever	4 (12.90)
Dizziness	3 (9.67)
Debilitation	6 (19.35)
Nausea or vomiting	1 (3.22)
Diarrhea	2 (6.44)
Tachycardia	1 (3.22)